(VIANEWS) – M&T Bank (MTB), Amgen (AMGN), Coca-Cola (KO) have the highest dividend yield stocks on this list.
| Financial Asset | Forward Dividend Yield | Updated (EST) |
|---|---|---|
| M&T Bank (MTB) | 3.55% | 2024-04-28 03:18:33 |
| Amgen (AMGN) | 3.33% | 2024-04-28 03:11:03 |
| Coca-Cola (KO) | 3.14% | 2024-04-28 03:18:01 |
| BlackRock Municipal Target Term Trust (BTT) | 2.73% | 2024-04-21 09:10:05 |
A little less 2K companies listed in the Nasdaq and NYSE pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. M&T Bank (MTB) – Dividend Yield: 3.55%
M&T Bank’s last close was $146.38, 1.71% below its 52-week high of $148.93. Intraday change was -0.46%.
M&T Bank Corporation operates as a bank holding company for Manufacturers and Traders Trust Company and Wilmington Trust, National Association that engages in the provision of retail and commercial banking products and services in the United States. The company operates through three segments: Commercial Bank, Retail Bank, and Institutional Services and Wealth Management. It offers a range of credit products and banking services, such as commercial lending and leasing, letters of credits, commercial real estate loans, and credit facilities secured by various commercial real estate to middle-market and large commercial customers. The company also provides customers deposit products, including demand, savings and time accounts, and other services; automobile and recreational finance loans, home equity loans and lines of credit, credit cards, and other loan products, as well as residential mortgage and real estate loans; business loans, cash management, payroll, and direct deposit services to consumers and small businesses through branch network, telephone banking, internet banking, and automated teller machines. In addition, it offers trustee, agency, investment management, security brokerage, and administrative services; personal trust, planning, fiduciary, asset management, family office, and other services; and investment products, including mutual funds and annuities, and other services for corporations and institutions, investment bankers, corporate tax, finance and legal executives, and other institutional clients. The company was founded in 1856 and is headquartered in Buffalo, New York.
Earnings Per Share
As for profitability, M&T Bank has a trailing twelve months EPS of $15.79.
PE Ratio
M&T Bank has a trailing twelve months price to earnings ratio of 8.52. Meaning, the purchaser of the share is investing $8.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.78%.
Moving Average
M&T Bank’s value is below its 50-day moving average of $140.85 and above its 200-day moving average of $132.52.
Volatility
M&T Bank’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.28%, a negative 0.04%, and a positive 1.40%.
M&T Bank’s highest amplitude of average volatility was 0.76% (last week), 1.48% (last month), and 1.40% (last quarter).
More news about M&T Bank.
2. Amgen (AMGN) – Dividend Yield: 3.33%
Amgen’s last close was $269.98, 18.12% under its 52-week high of $329.72. Intraday change was -1.01%.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Earnings Per Share
As for profitability, Amgen has a trailing twelve months EPS of $12.48.
PE Ratio
Amgen has a trailing twelve months price to earnings ratio of 21.42. Meaning, the purchaser of the share is investing $21.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 135.79%.
Previous days news about Amgen
- Insights into Amgen (amgn) Q1: wall street projections for key metrics. According to Zacks on Monday, 29 April, "View all Key Company Metrics for Amgen here>>>Shares of Amgen have demonstrated returns of -5% over the past month compared to the Zacks S&P 500 composite’s -2% change. ", "In light of this perspective, let’s dive into the average estimates of certain Amgen metrics that are commonly tracked and forecasted by Wall Street analysts."
More news about Amgen.
3. Coca-Cola (KO) – Dividend Yield: 3.14%
Coca-Cola’s last close was $61.74, 4.56% under its 52-week high of $64.69. Intraday change was -1.3%.
The Coca-Cola Company, a beverage company, manufactures, markets, and sells various nonalcoholic beverages worldwide. The company provides sparkling soft drinks, sparkling flavors; water, sports, coffee, and tea; juice, value-added dairy, and plant-based beverages; and other beverages. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers, such as restaurants and convenience stores. The company sells its products under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, caffeine free Diet Coke, Cherry Coke, Fanta Orange, Fanta Zero Orange, Fanta Zero Sugar, Fanta Apple, Sprite, Sprite Zero Sugar, Simply Orange, Simply Apple, Simply Grapefruit, Fresca, Schweppes, Thums Up, Aquarius, Ayataka, BODYARMOR, Ciel, Costa, Dasani, dogadan, FUZE TEA, Georgia, glacéau smartwater, glacéau vitaminwater, Gold Peak, Ice Dew, I LOHAS, Powerade, Topo Chico, AdeS, Del Valle, fairlife, innocent, Minute Maid, and Minute Maid Pulpy brands. It operates through a network of independent bottling partners, distributors, wholesalers, and retailers, as well as through bottling and distribution operators. The company was founded in 1886 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Coca-Cola has a trailing twelve months EPS of $2.47.
PE Ratio
Coca-Cola has a trailing twelve months price to earnings ratio of 23.6. Meaning, the purchaser of the share is investing $23.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 40.16%.
Volume
Today’s last reported volume for Coca-Cola is 9148660 which is 34.86% below its average volume of 14045400.
Moving Average
Coca-Cola’s value is below its 50-day moving average of $60.08 and below its 200-day moving average of $58.98.
More news about Coca-Cola.
4. BlackRock Municipal Target Term Trust (BTT) – Dividend Yield: 2.73%
BlackRock Municipal Target Term Trust’s last close was $20.41, 5.94% below its 52-week high of $21.70. Intraday change was 0%.
Blackrock Municipal 2030 Target Term Trust is a closed end fixed income mutual fund launched by BlackRock, Inc. The fund is managed by by BlackRock Advisors, LLC. It invests in fixed income markets. The fund invests primarily in investment grade municipal bonds that are exempt from regular federal income tax. It was formerly known as BlackRock Municipal Target Term Trust. Blackrock Municipal 2030 Target Term Trust was formed on August 30, 2012 and is domiciled in the United States.
Earnings Per Share
As for profitability, BlackRock Municipal Target Term Trust has a trailing twelve months EPS of $0.57.
PE Ratio
BlackRock Municipal Target Term Trust has a trailing twelve months price to earnings ratio of 35.81. Meaning, the purchaser of the share is investing $35.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.77%.
More news about BlackRock Municipal Target Term Trust.
